Molecular Profiling of Endometrial Cancer: An Exploratory Study in Aotearoa, New Zealand.
endometrial cancer
molecular
subtype
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Nov 2021
11 Nov 2021
Historique:
received:
23
09
2021
revised:
05
11
2021
accepted:
08
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Aotearoa, New Zealand, has one of the fastest-rising rates of endometrial cancer (EC) worldwide, increasing particularly in younger Māori and Pasifika women. There is a move towards using molecular profiling to direct treatment for each EC subtype. This study aimed to explore the molecular profiling of primary EC tissue in Aotearoa. We used the PORTEC guidelines for the molecular subtyping of 90 patients' samples into four categories: In total, 15 samples were MMRd, 9 were p53 abnormal, 8 were Surrogate markers for
Sections du résumé
BACKGROUND
BACKGROUND
Aotearoa, New Zealand, has one of the fastest-rising rates of endometrial cancer (EC) worldwide, increasing particularly in younger Māori and Pasifika women. There is a move towards using molecular profiling to direct treatment for each EC subtype.
AIM
OBJECTIVE
This study aimed to explore the molecular profiling of primary EC tissue in Aotearoa.
METHODS
METHODS
We used the PORTEC guidelines for the molecular subtyping of 90 patients' samples into four categories:
RESULTS
RESULTS
In total, 15 samples were MMRd, 9 were p53 abnormal, 8 were
CONCLUSION
CONCLUSIONS
Surrogate markers for
Identifiants
pubmed: 34830795
pii: cancers13225641
doi: 10.3390/cancers13225641
pmc: PMC8615986
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : CSRD VA
ID : 1
Pays : United States
Organisme : RANZCOG Arthur Wilson Memorial Scholarship
ID : 2
Références
Int J Mol Sci. 2021 Sep 27;22(19):
pubmed: 34638729
Int J Equity Health. 2019 Oct 28;18(1):163
pubmed: 31660988
Gynecol Oncol. 2021 May;161(2):621-628
pubmed: 33715893
Front Immunol. 2019 Apr 26;10:877
pubmed: 31105699
N Z Med J. 2018 Aug 17;131(1480):81-89
pubmed: 30116069
Cancer Immunol Res. 2019 May;7(5):784-796
pubmed: 30872264
Cancer Causes Control. 2019 Feb;30(2):121-127
pubmed: 30671687
Ther Adv Med Oncol. 2021 Aug 14;13:17588359211035959
pubmed: 34408794
Ann Oncol. 2018 May 1;29(5):1180-1188
pubmed: 29432521
Front Oncol. 2019 Oct 15;9:1040
pubmed: 31681578
J Pathol. 2020 Mar;250(3):323-335
pubmed: 31829442
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Clin Exp Immunol. 2020 May;200(2):108-119
pubmed: 31828774
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32900861
Br J Cancer. 2016 Aug 23;115(5):553-63
pubmed: 27490802
Cancer Treat Rev. 2018 Feb;63:40-47
pubmed: 29207310
J Pers Med. 2021 Jan 15;11(1):
pubmed: 33467460
J Natl Cancer Inst. 2014 Sep 10;106(9):
pubmed: 25214561
Front Oncol. 2021 Mar 19;11:640018
pubmed: 33816285
Bioinformatics. 2019 Oct 15;35(20):4200-4202
pubmed: 30903160
Oncol Lett. 2020 Nov;20(5):207
pubmed: 32963613
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S123-S131
pubmed: 29517499
J Clin Oncol. 2020 Oct 10;38(29):3388-3397
pubmed: 32749941
J Minim Invasive Gynecol. 2018 May - Jun;25(4):724-729
pubmed: 29223698
PLoS One. 2019 Mar 27;14(3):e0214318
pubmed: 30917185
Aust N Z J Obstet Gynaecol. 2020 Apr;60(2):250-257
pubmed: 31903554
Front Endocrinol (Lausanne). 2019 Jul 12;10:471
pubmed: 31354634